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Dominant Suppression of Inflammation via Targeted
Mutation of the mRNA Destabilizing Protein Tristetraprolin
Ewan A. Ross,*,1 Tim Smallie,*,1 Qize Ding,† John D. O’Neil,* Helen E. Cunliffe,*
Tina Tang,* Dalya R. Rosner,* Iva Klevernic,‡ Nicholas A. Morrice,x Claudia Monaco,{
Adam F. Cunningham,* Christopher D. Buckley,* Jeremy Saklatvala,{ Jonathan L. Dean,{
and Andrew R. Clark*
In myeloid cells, the mRNA-destabilizing protein tristetraprolin (TTP) is induced and extensively phosphorylated in response to
LPS. To investigate the role of two specific phosphorylations, at serines 52 and 178, we created amouse strain in which those residues
were replaced by nonphosphorylatable alanine residues. The mutant form of TTP was constitutively degraded by the proteasome
and therefore expressed at low levels, yet it functioned as a potent mRNA destabilizing factor and inhibitor of the expression of many
inflammatory mediators. Mice expressing only the mutant form of TTP were healthy and fertile, and their systemic inflammatory
responses to LPSwere strongly attenuated. Adaptive immune responses and protection against infection by Salmonella typhimurium
were spared. A single allele encoding the mutant form of TTP was sufficient for enhanced mRNA degradation and underexpres-
sion of inflammatory mediators. Therefore, the equilibrium between unphosphorylated and phosphorylated TTP is a critical
determinant of the inflammatory response, and manipulation of this equilibrium may be a means of treating inflammatory
pathologies. The Journal of Immunology, 2015, 195: 265–276.
T
he finely orchestrated programs of gene expression in
immune cells responding to stimulation are dictated not
only by transcriptional regulation but equally by post-
transcriptional processes, in particular the control of mRNA sta-
bility (1–4). Many cytokines, chemokines, and other immune
mediators are encoded by mRNAs that have intrinsically short
half-lives, with their rapid turnover being essential for timely
termination of immune responses. Furthermore, the modulation of
rates of mRNA destruction by pro- and anti-inflammatory agonists
is an important means of controlling the duration and quality of
those responses. For example, the p38 MAPK signaling pathway
is activated by proinflammatory stimuli and mediates transient
stabilization of many inflammatory mediator mRNAs (reviewed in
Ref. 5). The aberrant expression of proinflammatory mediators in
pathological conditions cannot be fully understood without in-
vestigating posttranscriptional mechanisms.
Tristetraprolin (TTP) is the founding member of a small family
of evolutionarily conserved, sequence-specific RNA binding pro-
teins, which is encoded by the Zfp36 gene in the mouse and
recognizes the optimum binding site WUAUUUAUW (where W is
adenosine or uridine) (6). TTP binds to this sequence element in
the 39 untranslated region (UTR) of target transcripts, including
Tnf and many other inflammatory factors. It then mediates re-
cruitment of the carbon catabolite repression protein 4/carbon
catabolite repression protein 4–associated factor 1 deadenylase
complex and thus promotes the shortening of the poly(A) tail of
the target mRNA (7–11). In most cases, this is rapidly followed by
the destruction of the mRNA body (12). Hence, TTP is a critical
negative regulator of expression of a large number of proin-
flammatory genes (6). Zfp362/2 mice lacking TTP protein have
a severe, pervasive inflammatory phenotype that includes ca-
chexia, dermatitis, autoimmunity, and inflammatory arthritis. The
phenotype is largely (although not exclusively) due to increased
stability of Tnf mRNA leading to increased expression of TNF
protein in the myeloid compartment (3, 6, 13).
A working model of the posttranscriptional regulation of pro-
inflammatory gene expression by the p38 MAPK pathway has
been built up using a variety of in vitro assays, transient trans-
fections of reporter construct, and studies of endogenous transcripts
in cells derived from knockout mice (reviewed in Refs. 14, 15).
According to this model, p38 MAPK activates the downstream
kinase MAPK-activated protein kinase 2 (MK2), which phos-
phorylates TTP at serines 52 and 178 (murine TTP residue
numbers), preventing the recruitment of the carbon catabolite re-
pression protein 4/carbon catabolite repression protein 4–associ-
ated factor 1 complex and hence inhibiting deadenylation and
promoting stabilization of TTP target transcripts. TTP is not
expressed by resting macrophages, and for a number of reasons its
accumulation depends on the p38 MAPK pathway. First, tran-
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scription of the Zfp36 gene is controlled by MK2 (15). Second,
p38 MAPK and MK2 regulate the stability of Zfp36 mRNA via an
autoregulatory loop in which TTP recognizes a binding site in its
own (i.e., Zfp36) 39 UTR (3, 16). Third, the same MK2-mediated
phosphorylations that cause inactivation of TTP protect it from
degradation by the proteasome (17, 18).
We and others have hypothesized that the complex, multilayered
regulation of TTP expression and function permits tight coupling
between the activity of the p38 MAPK pathway and the expression
of proinflammatory genes (3, 17, 18). In the early phase of an
inflammatory response, in which p38 MAPK activity is typically
high, TTP protein accumulates in a dormant form as the phos-
phorylation of serines 52 and 178 promotes protein stabilization
and inactivation. This permits the accumulation and translation of
TTP target transcripts that encode mediators of inflammation.
When p38 MAPK activity subsequently falls, TTP is activated
via dephosphorylation, likely by PP2A (19), and drives the off-
phase of the inflammatory response by promoting the rapid dead-
enylation of target transcripts. In vitro assays and overexpression
experiments provide circumstantial evidence in support of this
hypothesis. The experiments described in this study were intended
to test in vivo consequences of perturbing the MAPK p38-mediated
control of TTP function and to explore the concept of therapeutic
targeting of the equilibrium between phosphorylated and unphos-
phorylated TTP.
Materials and Methods
Reagents
LPS (Escherichia coli serotype EH100) was purchased from Enzo Life
Sciences. Other biochemicals were purchased from Sigma-Aldrich unless
otherwise stated. All media and sera were routinely tested for endotoxin
using the Limulus amebocyte lysate test (Lonza) and were rejected when
the endotoxin concentration was .0.1 U/ml.
Generation of a cell line stably expressing flag-TTP
RAW-MB01, a RAW264.7 clone expressing a tetracycline-responsive (Tet-
Off) transcription factor, was generated by stable transfection and selection
using blasticidin (2 mg/ml). LPS-induced expression of Tnf mRNA and
TNF protein in this clone was indistinguishable from that in the parental
RAW264.7 line (data not shown). Murine TTP cDNA with an N-terminal
flag tag was subcloned into the tetracycline-responsive expression vector
pTRE2Hyg (TaKaRa Bio). The vector was transfected into RAW-MB01,
and several clones resistant to hygromycin (100 mg/ml) were isolated.
Clone RAW-MB01-WT3.1 was used in the present study. Expression of
flag-TTP was found to be strongly inducible by LPS but only weakly re-
sponsive to tetracycline, because of leakiness of the tetracycline-regulated
promoter in RAW264.7 cells (data not shown).
Phosphoproteomics
RAW-MB01-WT3.1 cells were stimulated for 2 h with 10 ng/ml LPS and
lysed in lysis buffer (50 mM Tris-HCl [pH 7.5], 1 mM EDTA, 1 mM
EGTA, 1 mM Na3VO4, 10 mM sodium b-glycerophosphate, 5 mM sodium
pyrophosphate, 50 mM NaF, 0.27 M sucrose, 1% [w/v] Nonidet P-40,
1 mM DTT, 1 mg/ml pepstatin, 1 mM PMSF, 10 mM E64). All purifica-
tion steps were at 4˚C. Lysates were precleared overnight using protein
G–agarose beads and then applied to M2 anti-flag agarose beads for 4 h.
Beads were washed six times with LB plus 0.25 M NaCl and three times
with LB plus 0.15 M NaCl, and then flag-TTP was eluted in EB (50 mM
Tris-HCl [pH 7.5], 150 mM NaCl, 0.1 mM EGTA) containing 0.25 mg/ml
33 flag peptide. The eluate was subjected to SDS-PAGE, bands were vi-
sualized using colloidal Coomassie blue, excised, digested with trypsin,
and analyzed by liquid chromatography–mass spectrometry on an LTQ-
Orbitrap-XL essentially as described previously. Peptide mixtures were
separated on a 150 3 0.075 mm PepMapC18 column fitted to a Proxeon
Easy-LC and liquid chromatography–tandem mass spectrometry was
performed using multistage activation in the LTQ. Raw data files were
searched against Swiss-Prot database (160613) using Mascot 2.4 (Matrix
Science) and processed using Proteome Discoverer 1.3 software (Thermo
Scientific). Search criteria were: precursor mass tolerance, 20 ppm; tandem
mass spectrometry mass tolerance, 0.6 Da; enzyme, trypsin (KP/RP bonds
cleaved, two missed cleavages permitted); variable modifications, phos-
phorylation (STY) and oxidation (M); minimum peptide ion score, 20.
Extracted ion chromatography was performed using Proteome Discoverer
1.3 and Xcalibur software (Thermo Scientific).
Generation and testing of phospho-specific antisera
An antiserum specific for phosphorylated Ser52 was generated by immu-
nization of rabbits with the peptide LTGRSTpSLVEGR (Eurogentec). The
serum was precleared using the equivalent nonphosphorylated peptide and
then affinity purified against the phosphopeptide. An antiserum specific for
phosphorylated Ser178 was generated by immunization of rabbits with the
peptide LRQSIpSFSGLPSR (Division of Signal Transduction Therapy,
University of Dundee). The serum was affinity purified using the immu-
nizing peptide. Codons 52 and 178 in pGEX-TTP (20) were mutated from
serine to alanine codons using QuikChange (Agilent Technologies). Wild-
type GST-TTP and GST-TTP-S52A/S178A were purified as described
(20). In vitro phosphorylations were performed at 30˚C for 30 min with
3 mg recombinant TTP substrate and 100 mM ATP in the absence or
presence of 0.01 U purified MK2 (Millipore). Aliquots containing 100 ng
TTP were transferred to nitrocellulose and blotted with either phospho-
specific antisera or antiserum raised against total TTP (20).
Generation of Zfp36aa/aa strain
Targeting of the Zfp36 was performed with the assistance of Genoway (see
schematic in Fig. 2A). Homology arms were generated by PCR from
129Sv genomic DNA and sequenced in their entirety. The targeting con-
struct was created by sequential ligation of the two homology arms,
a neomycin cassette flanked by Cre recombinase recognition sites and
a synthetic DNA fragment (Top Gene Technologies) corresponding to part
of the Zfp36 intron and part of the second exon, incorporating serine to
alanine substitutions at codons 52 and 178. The construct encopasses a
9.5-kb region orthologous to Chr7:28,372,130–28,381,646 of the C57BL/6J
genome (build 38). The position of insertion of the neomycin cassette
corresponds to Chr7:28,378,880. The targeting construct was transfected
into 129Sv embryonic stem cells. Correct recombination of the Zfp36 locus
was confirmed by Southern blotting, PCR, and sequencing of genomic
DNA for two independent neomycin-resistant embryonic stem cell
clones. Recombinant embryonic stem cells were injected into C57BL/6J
blastocysts, which were then reimplanted into pseudo-pregnant C57BL/6J
females. Three males with .50% coat color chimerism were selected
for breeding with C57BL/6J female mice constitutively expressing Cre
recombinase (Cre deleter strain). Twenty-three of 23 pups had Agouti coat
color, suggesting germline transmission of the modified Zfp36 allele. In
three of those pups, correct excision of the neomycin cassette was con-
firmed by Southern blotting, genomic DNA sequencing, and PCR of ge-
nomic DNA with primers flanking the site of the neomycin insert: CLA1
forward (59-CACACCTGTCTAGTGCCCTTCGCTG-39) and CLA1 re-
verse (59-CCCAAATCAAAGCACACTGCTGCTC-39). Two Zfp36+/aa
males were used as founders of a breeding colony, with genotyping using
the above oligonucleoties. Initial experiments used littermate Zfp36+/+ and
Zfp36aa/aa mice. The strain has now been back-crossed against C57BL/6J
for 10 generations. Parallel, true breeding Zfp36+/+ and Zfp36aa/aa lines
were then established from progeny of Zfp36+/aa versus Zfp36+/aa mat-
ings, and were used in all experiments described in the present study.
Differences between Zfp36+/+ and Zfp36aa/aa mice were consistent
whether littermates or true-breeding Zfp36+/+ and Zfp36aa/aa lines were
used.
In vivo experiments and cell isolation
All animal experiments were approved by local ethical committees and
performed under UK Home Office project licenses. C57BL/6 mice were
purchased from Harlan Laboratories UK. All mice used were between 6 and
12 wk of age. To assess the response to LPS-induced systemic shock, mice
were injected i.p. with 5 mg/kg purified LPS (Serotype EH100, Enzo Life
Sciences) in 200 ml sterile PBS. Mice were culled 3 or 12 h after challenge,
peripheral blood was collected by cardiac puncture for serum isolation, and
tissues were frozen in liquid nitrogen for histology. Serum markers of
tissue damage were measured by the Clinical Pathology Service Labora-
tory at MRC Harwell (Didcot, U.K.). The response to bacterial infection
was assessed by challenging mice with 5 3 105 attenuated Salmonella
enterica serovar typhimurium as previously described (21).
Bone marrow–derived macrophages (BMMs) were generated from
hindlegs of humanely culled animals and differentiated in vitro with 100
ng/ml M-CSF (PeproTech) in 10% heat-inactivated FCS RPMI 1640
containing penicillin/streptomycin for 7 d. BMMs were plated at a density
of 1 3 106/ml in the appropriate cell culture plate at least 1 d prior to
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stimulation. Primary peritoneal macrophages were harvested by lavaging
the peritoneal cavity with 5 ml PBS containing 2 mM EDTA. Lavage fluid
was collected and cells were resuspended at 2 3 106/ml in DMEM sup-
plemented with 10% heat-inactivated FCS and penicillin/streptomycin.
Cells were plated and allowed to adhere for 1 h at 37˚C, before being
washed twice with media. The remaining adherent cells were .90%
F4/80+ macrophages as assessed by flow cytometry. Cells were rested over-
night before stimulation. Mesenteric and inguinal lymph node T cells were
negatively selected using Pan T Cell Isolation Kit II (Miltenyi Biotec) and
stimulated for 72 h with plate-bound anti-CD3ε and anti-CD28 (eBio-
science). Spleen cells were harvested as described (21) and stimulated for
6 h with plate-bound anti-CD3ε and anti-CD28, the last 3 h in the presence
of brefeldin A (3 mg/ml). Intracellular IFN-g was measured as described
(22), using a Cyan ADP flow cytometer (Dako) and FloJo software (Tree
Star).
Measurement of mRNA
RNA was extracted from BMMs using QIAshredder columns and RNeasy
Mini kits (Qiagen). cDNAwas generated using iScript cDNA synthesis kit
(Bio-Rad). Gene expression was quantified by real-time PCR on a Light-
Cycler 480 II (Roche) using SuperScript III platinum RT-PCR kit and
custom-synthesized oligonucleotide primers (Eurofins MWG) with SYBR
Premix Ex Taq (Lonza). Relative gene expression was calculated using the
DDCt method with Gapdh mRNA for normalization of RNA levels.
Sequences of oligonucleotides are available upon request from the authors.
For microarray analysis, RNAwas extracted as above and purified using
RNA Clean and Concentrator kits (Cambridge Bioscience). Hybridization
and analysis were performed by Oxford Gene Technology. Total RNA or
control RNAwere converted to labeled cRNAwith Cy3 or Cy5, respectively,
using a two-color low input Quick Amp labeling kit (Agilent Technologies).
Samples were hybridized onto SurePrint G3 mouse GE 8 3 60k slides and
read using a G2505C scanner (Agilent Technologies). The scanned images
were analyzed with Agilent Feature Extraction software 10.7.3.1 using
default parameters. Processed signal intensities were background subtracted
and spatially detrended.
RNA immunoprecipitation
BMMs (∼23 107) were left untreated or stimulated with 10 ng/ml LPS for
1 h, harvested, and washed twice with ice-cold PBS, then lysed in 1 ml ice-
cold polysome lysis buffer (100 mM KCl, 10 mM HEPES [pH 7.0], 5 mM
MgCl2, 0.5% Nonidet P-40, 1 mM DTT, 100 U/ml RNase inhibitor, pro-
tease inhibitor mixture [Roche]). Lysates were frozen at 280˚C, thawed,
and cleared by centrifugation in a chilled benchtop centrifuge at 13,000
rpm for 5 min. Protein A beads were washed three times in NT2 buffer
(150 mM NaCl, 50 mM HEPES [pH 7.4], 1 mM MgCl2, 5% BSA) and
then incubated overnight with TTP-specific antiserum or rabbit IgG. Beads
were washed four times with buffer NT2 minus BSA, plus 1 mM DTT,
15 mM EDTA, 100 U/ml RNase inhibitor, and protease inhibitors. Beads
were resuspended in the same modified NT2 buffer, added to macrophage
lysates, and incubated overnight. Beads were washed four times in buffer
NT2, and RNA was extracted using TRIzol reagent according to the
manufacturer’s instructions. An equal volume of isopropanol and 20 mg
glycogen were added, and RNA was precipitated by incubation at 220˚C
for 1 h and centrifugation at 13,000 rpm for 5 min at 4˚C. The pellet was
washed with 70% ethanol, resuspended in distilled water, and used as
a template for RT-PCR as described above.
Assessment of protein expression
Secreted factors in tissue culture supernatants and sera were quantified by
ELISA according to the manufacturer’s instructions (eBioscience), or by
using mulitplex bead capture assays and a Bio-Plex 200 analyzer (Bio-
Rad). Cell lysates were resolved on SDS-PAGE gels, probed with pri-
mary Abs, and immunoreactive proteins were visualized with HRP-coupled
secondary Abs and chemiluminescence reagents (Bio-Rad, Pierce, or Cell
Signaling Technology). Blots were visualized using the ChemiDoc MP im-
aging system and in some cases were quantified using Image Lab software
(Bio-Rad).
Adenoviral reporters
The construction of adenoviral reporter constructs containing the human
TNF 59 region, the TNF 59 region, and 39 UTR, or five tandem copies of an
NF-kB consensus was previously described, as was the method of mac-
rophage infection (23). Levels of viral infection were quantified by flow
cytometric assessment of GFP fluorescence. Luciferase assays were per-
formed using the Bright-Glo luciferase assay system (Promega). Lumi-
nescence was measured with a Centro LB 960 luminometer (Berthold
Technologies).
Histology and confocal microscopy
Spleens were snap frozen in liquid nitrogen immediately after exci-
sion and stored at 280˚C. Tissues were subsequently embedded in OCT
compound (Sakura Finetek) and 6-mm sections were cut and fixed in
acetone at 4˚C for 20 min. Sections were rehydrated in TBS and blocked
in 10% horse serum in TBS for 1 h at room temperature. Primary Abs
(rabbit anti-mouse TTP, H-120, Santa Cruz Biotechnology; sheep anti-
mouse IgD, Abcam; rat anti-mouse F4/80, AbD Serotec) or appropriate
species isotype controls were incubated overnight at 4˚C in blocking
buffer. Sections were washed three times in TBS and incubated for 1 h at
room temperature with secondary Abs (donkey anti-rabbit IgG–Alexa
Fluor 555, donkey anti-sheep IgG–Alexa Fluor 488, donkey anti-rat IgG–
Alexa Fluor 647; all Jackson ImmunoResearch Laboratories). Sections
were washed three times and mounted in DABCO (2.5% [w/v] dia-
zabicyclo-octane in 90% glycerol/10% PBS [pH 8.6]). Images were
captured by confocal microscopy using a Zeiss Axiovert UV microscope
with a 340 objective and processed using an LSM image browser
(Zeiss). Paraffin sections were dewaxed with xylene and rehydrated to
water through graded alcohol steps. H&E staining was performed using
standard methodologies.
Statistical analysis
GraphPad Prism (version 5.03) was used for statistical analysis. An un-
paired, two-tailed Student t test was applied for comparison of two groups.
For analysis of multiple groups, ANOVA was used with Bonferroni cor-
rection for multiple comparisons. A p value ,0.05 was considered sig-
nificant.
Probe intensity values for the microarray were analyzed with Partek
Genomics Suite version 6.6, build 6.13.0315. A two-way mixed model
ANOVA was performed on the entire dataset (55,681 probes) to calculate
pairwise contrasts consisting of a corrected step-up p value (false discovery
rate by the Benjamini–Hochberg step-up method, integrated into the Partek
software) and a fold change or ratio for difference in gene expression. The
ANOVA was calculated using the following factors: genotype, Zfp36+/+
versus Zfp36aa/aa; condition, unstimulated versus 1 h LPS. Weakly
expressed genes were filtered out when their sample intensity values (in-
verse log2) did not exceed an arbitrary value of 100 in at least two of three
replicate samples from LPS-treated BMMs of either genotype. Probes were
also filtered out that contained aberrant outliers (SD of three replicates
exceeding average of three replicates). The microarray data described in
this study have been submitted to the Gene Expression Ominbus at Na-
tional Center for Biotechnology Information (GSE68449). (http://www.
ncbi.nlm.nih.gov/).
Results
Gene targeting to disrupt MK2-mediated phosphorylation of
TTP
Previous studies described extensive phosphoproteomic analysis
of exogenous human TTP in HEK293 cells, which express little
or no endogenous TTP protein and were not stimulated (24, 25).
To identify phosphorylations occurring in a myeloid cell respond-
ing to a proinflammatory stimulus, epitope-tagged TTP was im-
munoprecipitated from a stably transfected and LPS-stimulated
RAW264.7 cell line, which expressed exogenous TTP at a level
only 2- to 3-fold higher than that of endogenous TTP. Phospho-
proteomic analysis unequivocally identified 14 sites of phos-
phorylation (11 serines, 2 threonines, and 1 tyrosine). Among
these were serines 52 and 178 (Fig. 1A). One tryptic peptide,
PGPELSPSPTSPTATPTTSSR, was phosphorylated at up to three
of the underlined residues. A second large peptide corresponding
to residues 188–234 of murine TTP contained up to four discrete
phosphorylations that could not be accurately assigned. Broadly,
the pattern of phosphorylation was similar to that of human TTP
in HEK293 cells (24, 25), although the previous studies did not
report phosphorylation of Ser60 (which corresponds to Ser52 of
the murine protein). It was confirmed by in vitro phosphorylation
of recombinant wild-type or mutagenized TTP, mass spectrometry,
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and two dimensional phosphopeptide mapping that MK2 effi-
ciently phosphorylates both Ser52 and Ser178 (data not shown).
Phospho-specific Abs were raised against Ser52 and Ser178, and
their specificity was established using wild-type or mutant GST-
TTP phosphorylated in vitro by MK2 (Fig. 1B). The ability of
the Abs to recognize recombinant TTP was dependent on MK2
and intact phospho-acceptor sites. The phospho-specific Abs both
recognized endogenous TTP immunoprecipitated from LPS-
treated RAW264.7 cells (Fig. 1C), providing further evidence
that these sites are phosphorylated in the context of the response
to LPS. Incubation of RAW264.7 cells with a p38 inhibitor
decreased both Ser52 and Ser178 phospho-TTP signals (data not
shown). As previously reported (17), inhibition of p38 MAPK also
decreased levels of total TTP. Therefore, at this stage it cannot be
formally concluded that in vivo phosphorylation of S52 and S178
is dependent on p38 MAPK. Evidence in support of this hypoth-
esis is presented below.
Functional consequences of TTP phosphorylation have so far
been studied in vitro or in transfected cells but not in vivo.
Therefore, homologous recombination was used to replace both
serine 52 and 178 codons with alanine codons in the endogenous
murine Zfp36 locus (Fig. 2A). We refer to the modified locus as
Zfp36aa and its protein product as TTPaa. In crosses between
heterozygous Zfp36+/aa parents, 105 of 442 (24%) of genotyped
pups were Zfp36aa/aa. The strain has been backcrossed against
the C57BL/6J background for 10 generations. Zfp36aa/aa mice
are healthy and fertile, with no discernible phenotype under stan-
dard conditions of maintenance. Leukocyte populations in spleen,
thymus, and peripheral blood were not significantly different from
those of wild-type littermates (data not shown).
TTPaa is weakly expressed
Zfp36aa mRNA was expressed at lower levels than Zfp36 mRNA
in BMMs (Fig. 2B), and this was accompanied by a decrease in
mRNA stability (Fig. 2C). TTP is thought to autoregulate its ex-
pression via binding to adenosine/uridine-rich elements in the
Zfp36 39 UTR and destabilization of Zfp36 mRNA (3, 16, 26). The
simplest interpretation of our findings is that the mutant form of
TTP has greater mRNA destabilizing activity and enhances the
degradation of its own (i.e., Zfp36aa) mRNA.
Relative to its wild-type counterpart, TTPaa was weakly
expressed in LPS-treated BMMs (Fig. 2D). On the basis of
scanning densitometry in four independent experiments, we esti-
mate an 80% decrease in levels. Because this was greater than the
decrease in mRNA expression, cycloheximide chases were per-
formed to investigate protein stability (Fig. 2E). Wild-type TTP
was relatively stable (top panel, lanes 2–4), but was rapidly de-
graded following addition of a p38 MAPK inhibitor (top panel,
lanes 5 and 6). In contrast, TTPaa was rapidly degraded whether
the p38 MAPK inhibitor was absent or present (third panel, lanes
2–6). A proteasome inhibitor protected TTPaa from degradation
(Fig. 2F, last two lanes). Taken together, these observations con-
firm that p38 MAPK-dependent phosphorylation of Ser52 and
Ser178 protects TTP protein from degradation by the proteasome
(17, 18). Therefore, the diminished expression of TTPaa appears
to result from (at least) two distinct phenomena: 1) an increased
rate of degradation of Zfp36aa mRNA, and 2) an increased rate of
degradation of TTPaa protein by the proteasome.
Selective impairment of responses to LPS in Zfp36aa/aa
macrophages
Microarray analysis was carried out to identify genome-wide
effects of Zfp36 gene targeting on the LPS responses of macro-
phages. Of 2130 transcripts significantly induced by 1 h treatment
with LPS, Zfp36aa/aa BMMs significantly underexpressed 165
(8%) (Table I). The proportion of LPS-induced transcripts that
were underexpressed by Zfp36aa/aa BMMs remained similar
when a 3-, 5-, or 10-fold cut-off for LPS response was applied, or
when the stimulus was applied for 4 h rather than 1 h (Table I,
Supplemental Table I, GSE68449). Clearly, mutation of the Zfp36
gene did not globally impair macrophage responses to LPS. In-
stead, expression of a distinct subset of genes was altered. Fig. 3A
FIGURE 1. Identification of sites of phosphorylation of TTP in LPS-stimulated myeloid cells. (A) Schematic of phosphorylation sites identified in
RAW264.7 cells expressing flag-TTP. Serines 52 and 178 are boxed. Pale gray bars indicate tetraprolin (PPPP) motifs. The dark gray bar indicates a large
tryptic peptide that contained up to four phosphorylations, only one of which (S188) could be assigned with confidence. Dotted lines indicate position of
C3H zinc finger motifs. (B) Validation of phospho-specific antisera. Phospho-specific antisera were raised against the phosphopeptides LTGRSTpSLVEGR
(S52) and LRQSIpSFSGLPSGR (S178). GST-TTP and GST-TTP-S52A/S178A (-TTPaa) were mock treated (2) or phosphorylated in vitro using MK2 (+)
as described in Materials and Methods, transferred to nitrocellulose, and dot blotted using either a previously described anti-TTP antiserum (20) or the
phospho-specific antisera. (C) LPS-induced phosphorylation of endogenous murine TTP at serines 52 and 178. RAW264.7 cells were stimulated with 10 ng/
ml LPS for the indicated times, lysates were prepared, and endogenous TTP was immunoprecipitated using an antiserum raised against the N terminus of
murine TTP (20). Immunoprecipitates were Western blotted using either phospho-specific antisera or an anti-TTP antiserum, with HRP-conjugated protein
G for detection. The experiment was performed twice for each phospho-specific antiserum.
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illustrates in heat map form 24 transcripts that were induced at
least 3-fold by LPS and significantly underexpressed by Zfp36aa/aa
BMMs. So far, 12 of these differentially expressed transcripts
have been validated by quantitative RT-PCR (Figs. 2B, 3B and
data not shown; also see Fig. 5B), with good agreement between
microarray-based and quantitative RT-PCR–based measurements
(Fig. 3B). The list of underexpressed transcripts at 1 h included
Tnf, Cxcl1, Cxcl2, and Il10, all of which are well-established
targets of negative regulation by TTP in myeloid cells (6). Zfp36
itself was also significantly underexpressed, consistent with the
suggestion that TTP autoregulates its own expression. Two alter-
native F3 transcripts were underexpressed by Zfp36aa/aa BMMs.
F3 encodes tissue factor, an initiator of coagulation that has re-
cently been identified as a target of TTP in macrophages (27).
Ier3, Pim1, and Lif were previously identified as TTP targets
in cell types other than primary macrophages (28–30). To our
knowledge, Areg and Clcf1 have not been identified as targets of
TTP; however, their 39 UTRs have highly conserved adenosine/
uridine-rich elements with matches to the consensus TTP binding
sequence UAUUUAU (Fig. 3C). As expected, Tnf and Cxcl1
mRNAs were detected in TTP immunoprecipitates from LPS-
activated wild-type BMMs (Fig. 3D). F3 and Clcf1 mRNAs were
also enriched in TTP immunoprecipitates, whereas Bcl3 mRNA,
which lacks a consensus TTP binding sequence, was strongly in-
duced by LPS but did not interact with TTP. As an additional
negative control, Gapdh mRNA was not enriched in TTP immu-
noprecipitates. These observations confirm that tissue factor ex-
pression is regulated by TTP, and they suggest that Clcf1 may also
be an authentic novel target of TTP. Genome-wide alterations of
expression may therefore be a useful starting point for the identi-
fication of transcripts regulated by the p38 MAPK/MK2/TTP axis
in macrophages or other cell types.
A number of cytokine- and chemokine-encoding transcripts were
found among those underexpressed by Zfp36aa/aa BMMs. To
FIGURE 2. Generation and initial characterization of the Zfp36aa/aa strain. (A) Schematic of gene targeting strategy. Exons are shown as boxes, Flox
sites as arrowheads. The first downward arrow represents homologous recombination of the targeting fragment into the Zfp36 locus, and the second
represents Cre-mediated excision of the neomycin cassette. Left and right arrows represent the primers used in genotyping, that is, CLA1-For and CLA1-
Rev. A representative genotyping gel is shown for three litters of mice born from Zfp36+/aa crosses. The wild-type locus yields a 234-bp PCR product, the
modified locus a 328-bp product. (B) Zfp36+/+ and Zfp36aa/aa BMMs were treated with 10 ng/ml LPS for 1, 2, 4, and 8 h, and Zfp36 mRNAwas measured
by quantitative PCR with normalization first against Gapdh then against expression level in Zfp36+/+ cells treated with LPS for 1 h. Means 6 SEM of four
independent experiments are shown. ***p , 0.005. (C) Zfp36+/+ and Zfp36aa/aa BMMs were treated with 10 ng/ml LPS for 4 h, actinomycin D (AMD;
5 mg/ml) and DRB (50 mM) were added, and the subsequent decay of Zfp36mRNAwas monitored by quantitative PCR. Means6 SEM of four independent
experiments are shown. (D) Zfp36+/+ and Zfp36aa/aa BMMs were treated as in (B) and levels of TTP protein were assessed by Western blotting. (E) As
indicated in the schematic, Zfp36+/+ and Zfp36aa/aa BMMs were treated with LPS for 2 h, then 5 mg/ml cycloheximide (CHX) was added in the presence
of 5 mM SB202190 (SB) or vehicle control (0.01% DMSO). Cells were harvested at 0, 2, 3, or 6 h as indicated, and TTP was detected by Western blotting.
(F) As indicated in the schematic, Zfp36+/+ and Zfp36aa/aa BMMs were treated with LPS for 4 h, then cycloheximide (CHX) was added in the presence of
5 mg/ml MG132 or vehicle control (0.01% DMSO). Cells were harvested at 0, 4, 5, or 6 h as indicated, and TTP was detected by Western blotting. Western
blots in (D)–(F) are representative of at least three independent experiments.
Table I. Genome-wide dysregulation of responses to LPS in Zfp36aa/aa BMMs
LPS-Induced Transcripts
1 h 4 h
↓ in Zfp36aa/aa ↑ in Zfp36aa/aa ↓ in Zfp36aa/aa ↑ in Zfp36aa/aa
All 2130 165 (8%) 60 (3%) 4933 291 (6%) 151 (3%)
.3-fold 434 24 (6%) 14 (3%) 1441 103 (7%) 47 (3%)
.5-fold 250 17 (7%) 10 (4%) 897 70 (8%) 29 (3%)
.10-fold 142 14 (10%) 6 (4%) 476 37 (8%) 13 (3%)
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extend this observation a preliminary experiment was carried out
using an Ab array to survey secretion of inflammatory mediator
proteins by LPS-treated Zfp36aa/aa BMMs (Supplemental Fig. 1).
Expression of TNF, CCL3, CXCL1, CXCL2, CXCL10, IL-1B,
CSF2, and other cytokines or chemokines was lower in Zfp36aa/aa
BMMs, whereas the expression of CCL2 and TIMP1 was unaltered.
Many of these changes in the response to LPS are confirmed and
discussed in greater detail below.
The effects of TTP mutation on the response to LPS might be
explained by alterations in NF-kB or MAPK signaling pathways
(28, 31, 32) or otherwise by inhibition of transcription (33).
However, LPS-induced activation of an NF-kB reporter was in-
distinguishable between Zfp36+/+ and Zfp36aa/aa BMMs (Fig. 4A,
upper panel). In the same experiment, TNF protein was under-
expressed by Zfp36aa/aa BMMs (Fig. 4A, lower panel). A re-
porter construct in which luciferase expression is driven by the
TNF promoter (23) was similarly responsive to LPS in Zfp36aa/aa
and Zfp36+/+ BMMs (Fig. 4B, upper panel). In contrast, a reporter
containing both the TNF promoter and 39 UTR was significantly
less responsive to LPS in Zfp36aa/aa BMMs, suggesting that the
inhibitory effect of the TTP mutation depends on the 39 UTR
rather than the promoter of the Tnf gene. In the same experiment,
endogenous TNF protein was underexpressed by Zfp36aa/aa
BMMs (Fig. 4B, lower panel). As a means of assessing transcription
of the endogenous Tnf gene, unspliced primary transcript levels
were measured in Zfp36+/+ and Zfp36aa/aa BMMs. In com-
parison with wild-type controls, Zfp36aa/aa BMMs expressed
lower amounts of mature Tnf mRNA but unchanged amounts of
Tnf primary transcript (data not shown). LPS-induced activation
of MAPK pathways was also indistinguishable in Zfp36aa/aa
and Zfp36+/+ BMMs (Fig. 4C). Although targeted mutation of
TTP altered the expression of a subset of LPS-induced genes,
we found no evidence that it did so by altering NF-kB activation,
MAPK signaling, or transcription.
To further investigate the properties of Zfp36aa/aa macro-
phages, we focused on well-known TTP targets, TNF, CXCL1,
and IL-10. All of these proteins were consistently underexpressed
by Zfp36aa/aa macrophages throughout a 12-h time course, dem-
onstrating that the TTP mutation does not merely delay the re-
sponse to LPS (Fig. 5A). The corresponding mRNAs were also
consistently underexpressed (Fig. 5B), and their half-lives were
decreased (Fig. 5C). Accelerated degradation of other known TTP
target transcripts such as F3 and Cxcl2 was also demonstrated in
Zfp36aa/aa BMMs (data not shown). To confirm that the under-
expression of cytokines or chemokines was not an artifact of
the in vitro differentiation of BMMs, peritoneal macrophages of
.90% purity were isolated from Zfp36+/+ and Zfp36aa/aa mice
and stimulated with LPS. Again, there was consistent under-
expression of TNF and CXCL1 by Zfp36aa/aa macrophages
(Fig. 5D). Expression of IL-10 was very low, and neither the re-
sponse to LPS nor the difference between Zfp36+/+ and Zfp36aa/aa
macrophages achieved statistical significance. These experiments
confirm that although Zfp36aa/aa macrophages express low levels
of TTP protein, this mutant form of TTP is highly active and pro-
motes destabilization of target mRNAs, many of which are involved
in the inflammatory response to TLR4 engagement.
Zfp36aa/aa mice display decreased systemic responses to LPS
Tissue-specific deletion of the Zfp36 gene in myeloid cells ren-
dered mice extremely sensitive to LPS-induced endotoxemia (3,
13). It was hypothesized that a gain of function mutation of TTP
would have the opposite effect. Systemic challenge of Zfp36+/+
mice by i.p. injection of LPS increased the expression of TTP
protein in spleen (Fig. 6A). TTP staining was principally cyto-
plasmic as expected, weak in the B and T cells of the white pulp,
FIGURE 3. Microarray analysis of differential gene expression in Zfp36+/+ and Zfp36aa/aa BMMs. (A) Zfp36+/+ and Zfp36aa/aa BMMs were stimulated
with 10 ng/ml LPS for 1 h, RNAwas isolated, and gene expression was analyzed by Agilent microarray. Transcripts upregulated at least 3-fold by LPS and
significantly (p , 0.05) underexpressed by Zfp36aa/aa BMMs are indicated. The heat map represents average normalized intensity values from three
independent samples per condition, ranked in order of relative expression level in Zfp36aa/aa BMMs (i.e., F3 being the most strongly underexpressed
transcript). Blue represents low and red high relative expression. The p values were calculated by two-way ANOVA test using Partek genomics suite. (B)
Zfp36+/+ and Zfp36aa/aa BMMs were stimulated with 10 ng/ml LPS for 1 h and selected transcripts were measured by quantitative PCR. For comparison,
microarray-based quantifications are illustrated on the same graphs. In each case, expression levels were normalized against those in LPS-treated Zfp36+/+
BMMs. Means 6 SEM of three (microarray) or four (quantitative PCR) independent experiments are indicated. (C) Possible TTP binding sites (AUUUA
pentamer motifs indicated by horizontal lines) in the 39 UTRs of selected transcripts. (D) Zfp36+/+ BMMs were left untreated or stimulated with 10 ng/ml
LPS for 1 h. Immunoprecipitation was carried out using an antiserum against murine TTP or a rabbit IgG control, and the indicated transcripts were
detected by RT-PCR. Input RNA from untreated or LPS-stimulated BMMs was also amplified under identical conditions.
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most evident in F4/80+ red pulp macrophages, but also detectable
in some F4/802 cells. Although this method is not highly quan-
titative, expression of TTPaa protein appeared to be weaker than
that of the wild-type protein (Fig 6A, compare second and fourth
panels). Serum levels of CCL2, CXCL2, IL-1B, IL-10, IL-12p70,
IL-17, and TNF were elevated in response to LPS and present at
significantly lower levels in serum of Zfp36aa/aa mice both 3 and
12 h after injection of LPS (Fig. 6B). CXCL1 was significantly
underexpressed by Zfp36aa/aa mice at the 12 h time point.
Underexpression of CXCL1 by Zfp36aa/aa mice at the 3 h time
point was not statistically significant in the experiments shown,
but it was so in other, similar experiments (see figures 8D and 5D
of the accompanying manuscript, that is, Ref. 34). Creatinine and
blood urea nitrogen (serum markers of renal damage) and alanine
transaminase (a marker of hepatic damage) were elevated in
Zfp36+/+ mice 12 h after injection of LPS (Fig. 6C). In Zfp36aa/aa
mice, these markers of LPS-induced organ damage were increased
only marginally or not significantly.
Acquired immune responses to S. typhimurium are not strongly
impaired in Zfp36aa/aa mice
The mutation of two serine codons effectively increased TTP
activity by preventing its inactivation, impaired the expression of
several inflammatory mediators, and conferred significant pro-
tection in an experimental model of endotoxemia. However, these
codons are subject to strong positive selective pressure, apparently
being conserved throughout vertebrate evolution (25). It was hy-
pothesized that the loss of phosphorylation-mediated dynamic
control of TTP function may impair adaptive immune responses,
causing increased susceptibility to pathogens. By way of prece-
dent, disruption of the Mk2 gene (encoding the kinase that phos-
phorylates serines 52 and 178 of TTP) increased susceptibility to
the intracellular pathogen Listeria monocytogenes (35). To test the
hypothesis, Zfp36+/+ and Zfp36aa/aa mice were inoculated with
an attenuated strain of S. typhimurium. In this well-established
model of infectious disease (22, 36), bacteria typically peak in
numbers in the liver and spleen ∼7 d after inoculation, with most
being cleared by day 55. Clearance of this strain of Salmonella is
mediated by a Th1 adaptive immune response and is highly de-
pendent on IFN-g, but not TNF (22, 37).
Bacterial loads were significantly higher in spleens and livers of
Zfp36aa/aa mice 21 d after inoculation, but they were comparable
to those in wild-type mice by day 55 (Fig. 7A). Pathogen-induced
expansion and subsequent contraction of the spleen followed
identical time courses in Zfp36+/+ and Zfp36aa/aa mice (Fig. 7B).
Zfp36+/+ and Zfp36aa/aa mice were vaccinated twice with PBS or
purified S. typhimurium porin proteins prior to challenge with live
S. typhimurium. The immunization gave similarly strong (.97.5%)
protection against the establishment of bacterial infection in both
strains of mice (Fig. 7C).
IFN-g is reported to be a target of negative regulation by TTP
(38). The ability of Zfp36aa/aa mice to clear an S. typhimurium
infection was therefore surprising and prompted us to investigate
the effect of TTP mutation on the expression of IFN-g by T cells.
Stimulation of Zfp36+/+ and Zfp36aa/aa splenocytes via CD3 and
CD28 induced similar numbers of IFN-g–expressing cells and
similar secretion of IFN-g protein (Fig. 7D, 7E). In summary,
we have not yet found evidence of impaired adaptive immune
responses in the Zfp36aa/aa mouse, consistent with its ability to
both clear an S. typhimurium infection and mount an effective
response to vaccination against this pathogen.
TTPaa functions as a dominant inhibitor of inflammatory gene
expression
Substitution of two phospho-acceptor sites of TTP by non-
phosphorylatable residues appeared to cause a gain of function,
increasing the rate of degradation of target mRNAs and impairing
the expression of inflammatory mediators. To test whether the
mutant allele exerts a dominant phenotype in the presence of
a wild-type allele, Zfp36+/+ and Zfp36aa/aa mice were bred to
generate heterozygotes. All of these mice are derived from the
same breeding program and have as near as possible the same
genetic background with the exception of the Zfp36 locus. As
previously shown, the expression of TTP protein was high in
Zfp36+/+ BMMs and comparatively low in Zfp36aa/aa BMMs
(Fig. 8A). In heterozygous BMMs, the levels of TTP were inter-
mediate, with an estimated 10–20% of this being the mutant form
of TTP. Rates of degradation of Tnf and Cxcl1 mRNAwere similar
in Zfp36+/aa and Zfp36aa/aa BMMs, and greater than in Zfp36+/+
BMMs (Fig. 8B). CXCL1, CXCL2, IL-10, IL-12p70, and TNF
were all significantly underexpressed by both Zfp36+/aa and
Zfp36aa/aa BMMs, with no significant difference between these
FIGURE 4. Underexpression of TNF in Zfp36aa/aa BMMs does not in-
volve altered transcription, NF-kB signaling, or MAPK signaling. (A) Zfp36+/+
or Zfp36aa/aa BMMs were transduced with an adenoviral vector expressing
firefly luciferase under the control of four tandem consensus NF-kB binding
sites. Transduced cells were rested overnight and then stimulated with LPS for
2 h. Luciferase activity was measured (upper panel) and secreted TNF protein
was measured (lower panel). Graphs represent means 6 SEM of measure-
ments from three independent BMM cultures of each genotype. (B) Zfp36+/+
or Zfp36aa/aa BMMs were transduced with adenoviral vectors expressing
firefly luciferase under the control of either the Tnf 59 region alone or both the
Tnf 59 and 39 regions. Cells were rested overnight and then stimulated with
LPS for 8 h. Luciferase activity was measured (upper panel) and secreted
TNF protein was measured (lower panel). Graphs represent means6 SEM of
measurements from three independent BMM cultures of each genotype. (C)
Zfp36+/+ or Zfp36aa/aa BMMs were treated with 10 ng/ml LPS for 0–240
min as indicated, and lysates were prepared and Western blotted using Abs
specific for phosphorylated (activated) p38 MAPK, ERK, or JNK. b-Actin
was blotted as a loading control. Blots are representative of two independent
experiments. *p , 0.05, **p , 0.01, ***p , 0.005.
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genotypes (Fig. 8C). The LPS-induced expression of CCL2 did not
differ significantly between Zfp36+/+, Zfp36+/aa, and Zfp36aa/aa
BMMs, confirming that the targeted mutation of TTP phospho-
acceptor sites does not globally impair the response to engage-
ment of TLR4. After i.p. injection of LPS, serum levels of
CXCL1, CXCL2, IL-10, and IL-12p70 were significantly lower in
both Zfp36aa/aa and Zfp36+/aa than in Zfp36+/+ control mice
(Fig. 8D). In the cases of CXCL1 and IL-10, there were small but
statistically significant differences in expression between Zfp36aa/aa
and Zfp36+/aa mice. There was a small but statistically significant
reduction in the levels of CCL2 in serum of LPS-treated Zfp36aa/aa
and Zfp36+/aa mice. TTPaa therefore appears to function as
a dominant mRNA destabilizing factor and inhibitor of inflam-
matory gene expression, even when in competition with a large
excess of wild-type protein.
Discussion
The substitution of only two codons of the endogenous murine
locus encoding TTP gave rise to a strong and dominant hypoin-
flammatory phenotype that is (as far as we are aware) unprece-
dented for such a minimal genetic modification. The expression of
several inflammatory mediators was impaired in LPS-treated peri-
toneal or bone marrow–derived Zfp36aa/aa macrophages. Organ
damage and systemic expression of inflammatory mediators in
response to LPS were likewise diminished in Zfp36aa/aa mice.
In some cases (e.g., CXCL2, IL-17), serum levels were .10-fold
lower in Zfp36aa/aa mice than in wild-type controls. We also
found that the genetically modified mice were protected in
other models of inflammatory pathology (E.A. Ross, T. Smallie,
C.D. Buckley, J.L. Dean, and A.R. Clark, manuscripts in prepa-
ration). Note that TTP has been identified as a putative tumor
suppressor, which limits the expression of many regulators of
cell cycle progression and survival. Loss of expression or
phosphorylation-mediated inactivation of TTP have been linked to
poor prognosis in several types of cancer (39–41). This raises the
intriguing prospect, now under investigation, that the Zfp36aa/aa
mouse may have a degree of protection in some experimental
models of cancer.
It has been suggested that TTP decreases expression of in-
flammatory mediators in part by impairing the activation of NF-kB
(31, 42, 43). Although we did not directly test this hypothesis, our
observations suggest that the enhanced anti-inflammatory function
of TTPaa is related to the canonical mechanism of mRNA de-
stabilization rather than involving inhibition of NF-kB signaling.
Accordingly, several known mRNA targets of TTP were degraded
at increased rates in Zfp36aa/aa cells, whereas there was no evi-
dence of impaired NF-kB function or decreased transcription of
Tnf, a well-characterized NF-kB–dependent gene. The phenotype
reflects the inability of TTPaa to be inactivated via p38 MAPK–
MK2 signaling. TTP has also been reported to impair translation
of target transcripts, and phosphorylation of Ser52 and Ser178 to
alleviate this effect (13, 15). In our hands, decreases in expression
of cytokines and chemokines by Zfp36aa/aa BMMs were gener-
ally accompanied by decreases in the stability and the steady-state
levels of the corresponding mRNAs. However, it cannot be ruled
out that decreased mRNA translation also contributes to the
underexpression of inflammatory mediators by Zfp36aa/aa cells or
animals. If this proves to be correct, experiments such as micro-
arrays, based on quantification of steady-state mRNA, may un-
derestimate the impact of the Zfp36 mutation.
FIGURE 5. TTPaa decreases expression of target genes via increased mRNA degradation. (A) Zfp36+/+ and Zfp36aa/aa BMMs were treated with 10 ng/
ml LPS for 1, 2, 4, 8, or 12 h, supernatants were harvested, and the indicated factors were measured by ELISA. Means6 SD of triplicate measurements are
shown for one representative of four independent experiments. (B) Zfp36+/+ or Zfp36aa/aa BMMs were treated with 10 ng/ml LPS for 1, 2, 4, or 8 h and the
indicated mRNAs were measured by quantitative PCR with normalization to Gapdh and against the Zfp36+/+ 1 h time point. Means 6 SEM of three
independent experiments are shown. (C) Zfp36+/+ or Zfp36aa/aa BMMs were treated with 10 ng/ml LPS for 1 h and then DRB (50 mM) and actinomycin D
(AMD, 5 mg/ml) were added. The indicated mRNAs were measured by quantitative PCR at 0, 1, or 2 h after addition of DRB and AMD and normalized to
the 0 h time point within each genotype. Means 6 SEM of three to four independent experiments are shown. (D) Freshly isolated Zfp36+/+ and Zfp36aa/aa
peritoneal macrophages were treated with 10 ng/ml LPS for 1, 2, 4, and 8 h, supernatants were harvested, and levels of the indicated cytokines were
measured by multiplex bead capture assay. Means 6 SEM from four mice of each genotype are shown. *p , 0.05, **p , 0.01, ***p , 0.005.
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Expression of TTPaa was ∼5-fold lower than that of the wild-
type protein. At least two distinct phenomena contributed to this
underexpression. First, the stability of Zfp36mRNAwas decreased
in cells expressing the mutated form of TTP, supporting previous
suggestions that TTP autoregulates its expression via destabili-
zation of its own mRNA (3, 16, 26). Second, TTPaa was consti-
FIGURE 7. Zfp36aa/aa mice retain effective acquired immune responses to S. typhimurium. (A) Zfp36+/+ and Zfp36aa/aa mice were injected i.p. with 5 3 105
S. typhimurium.Mice were sacrificied at days 7, 21, or 55, spleens and livers were dissected out, and bacterial burdens in these organs were measured. Graphs represent
data from four mice of each genotype. (B) Spleens were weighed in control, noninoculated mice or at days 7, 21, or 55 after inoculation with S. typhimurium. The graph
represents data from four mice of each genotype. (C) Four mice of each genotype were either immunized twice with purified porin protein or mock-immunized with PBS
and then inoculated with 53105 S. typhimurium. Bacterial loads in spleen were measured at day 7. (D) Whole splenocytes were stimulated for 6 h using plate-bound anti-
CD3 and anti-CD28, and intracellular expression of IFN-g in CD3+CD4+ T cells was assessed by flow cytometry. Graph shows mean 6 SEM from four mice of each
genotype. (E) Lymph node T cells were isolated from Zfp36+/+ or Zfp36aa/aamice, stimulated for 72 h using plate-bound anti-CD3 and anti-CD28, and secreted IFN-g
was measured. Graph shows mean6 SEM from three mice of each genotype. Representative of three independent experiments. *p, 0.05, **p, 0.01, ***p, 0.005.
FIGURE 6. Zfp36aa/aa mice are protected from experimental endotoxemia. (A) Zfp36+/+ and Zfp36aa/aa mice were injected i.p. with LPS (5 mg/kg) for 12 h
and expression of TTP was assessed by confocal imaging of spleen cryosections stained with anti-IgD (green), anti-TTP (red), or F4/80 (blue, original objective lens
magnification340). Scale bars, 20 mm. Images are representative of four individual mice per group. (B) Zfp36+/+ and Zfp36aa/aamice were injected i.p. with LPS
(5 mg/kg). After 3 or 12 h mice were exsanguinated and serum levels of cytokines were measured by multiplex bead capture assay. Graphs show mean 6 SEM
cytokine concentrations from 10 mice of each genotype at 3 and 12 h, and five untreated mice. (C) Serum levels of tissue damage markers were measured at the 12 h
time point in the same sera as in (B). *p , 0.05, **p , 0.01, ***p , 0.005.
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tutively unstable, whereas wild-type TTP protein was stabilized in
a p38 MAPK-dependent manner. This confirms that p38 MAPK-
dependent phosphorylation of TTP at Ser52 and Ser178 protects
it from proteasomal degradation (17, 18). Despite this decrease
of expression, the phenotype represents a gain of function, as
demonstrated most clearly by the behavior of heterozygous
(Zfp36+/aa) mice or macrophages derived from them. Their ex-
pression of inflammatory mediators was as low, or almost as low,
as in Zfp36aa/aa mice or macrophages. Similar half-lives of target
mRNAs and levels of expression of inflammatory mediators in
Zfp36+/aa and Zfp36aa/aa macrophages imply that TTPaa effec-
tively competes with an excess of wild-type TTP to promote more
rapid mRNA degradation. One possible explanation is that the
phosphorylation of Ser52 and Ser178 decreases the affinity of TTP
for RNA, so that the nonphosphorylatable mutant has a competi-
tive advantage in binding to target sequences. The difference in
expression of both TTPaa protein and its mRNA targets makes it
extremely difficult to test this hypothesis directly in Zfp36aa/aa
macrophages. However, other researchers have used biochemical
methods to demonstrate MK2-mediated decreases in mRNA binding
affinity of TTP (44, 45).
The results described in the present study emphasize that the
equilibrium between phosphorylated and unphosphorylated TTP
(with respect to serines 52 and 178) plays a crucial role in de-
termining the inflammatory output of macrophages. The hetero-
zygous phenotype suggests that quite a small shift in favor of
the dephosphorylated form could have strong anti-inflammatory
consequences. It follows that endogenous factors or therapeutic
reagents could exert anti-inflammatory effects by influencing the
phosphorylation/dephosphorylation equilibrium. As an example of
the former, an accompanying paper shows that dual specificity
phosphatase 1 limits inflammatory responses in vitro and in vivo
partly by modulating the phosphorylation status of TTP (34).
There are at least four possible methods for therapeutic targeting
of the equilibrium: 1) Inhibitors of p38 MAPK destabilize in-
flammatory mediator mRNAs by activating TTP (46, 47). How-
ever, despite clear therapeutic effects in experimental models of
acute and chronic inflammation, these compounds do not have
sustained clinical benefits in humans (48). A possible explanation
for their transient anti-inflammatory action is that in a chronic
setting they prevent the accumulation of TTP protein and there-
fore have little or no effect on target mRNA stability (46, 49).
2) Disruption of the gene encoding MK2 impairs inflammatory
responses of macrophages, identifying MK2 as a candidate target
for novel anti-inflammatory drugs (15). However, there are sig-
nificant technical challenges to the development of MK2 inhib-
itors (50). 3) It may be possible to increase TTP activity and
downregulate expression of inflammatory mediators via agonism
of PP2A. Increasing PP2A activity is already under investigation
as a therapeutic approach in cancer and neurodegenerative disease
FIGURE 8. TTPaa is a dominant inhibitor of inflammatory gene expression. (A) Zfp36+/+, Zfp36+/aa, and Zfp36aa/aa BMMs were treated with 10 ng/ml
LPS for 0, 4, or 8 h and expression of TTP protein was determined by Western blotting. b-Actin was blotted as a loading control. Results are representative of
four similar experiments. (B) Zfp36+/+, Zfp36+/aa, and Zfp36aa/aa BMMs were treated with 10 ng/ml LPS for 1 h and then DRB (50 mM) and actinomycin D
(AMD, 5 mg/ml) were added. The indicated mRNAs were measured by quantitative PCR at 0, 15, 30, 60, or 120 min after addition of DRB and AMD and
normalized to the 0 h time point within each genotype. Means 6 SEM of three to four independent experiments are shown. Error bars are obscured by the
symbols. (C) Zfp36+/+, Zfp36+/aa,and Zfp36aa/aa BMMs were treated with 10 ng/ml LPS for 4 h and levels of the indicated cytokines in the supernatants were
measured by multiplex bead capture assay. Means 6 SEM from four mice of each genotype are shown. (D) Zfp36+/+, Zfp36+/aa, and Zfp36aa/aa mice were
injected i.p. with LPS (5 mg/kg). After 3 h mice were humanely culled, exsanguinated, and serum levels of cytokines were measured by multiplex bead capture
assay. Graphs show means 6 SEM cytokine concentrations from at least four mice of each genotype. *p , 0.05, **p , 0.01, ***p , 0.005.
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(51). 4) In principle, protection of unphosphorylated TTP from
proteasome-mediated degradation should shift the balance in favor
of degradation of proinflammatory mRNAs. A recent publication
describes ubiquitin-independent degradation of TTP as a conse-
quence of the recognition of unstructured protein domains by the
proteasome (52). This may provide a starting point for attempts to
block the degradation of TTP protein.
Any discussion of therapeutic targeting of TTP needs to be
tempered with some caution. Serines 52 and 178 and surrounding
residues are conserved throughout vertebrates, implying that MK2-
mediated phosphorylation of TTP is an evolutionarily ancient
mechanism, subject to strong selective pressure. We hypothesized
that Zfp36aa/aa mice may have a defect in the acquired immune
response to infection. To test this hypothesis we used an attenu-
ated strain of Salmonella, which gives rise to a well-characterized,
Th1-dominated response (22, 36, 37). The infection is normally
cleared within ∼50–60 d, in a manner that depends on IFN-g but
appears independent of TNF. We found only a slight delay in
clearance of the bacterium by Zfp36aa/aa mice. Total IgG Ab
titers against the immunodominant Ag porin were unaltered, al-
though there was some evidence of subtle alterations of Ig class
switching, which require further investigation (data not shown).
Vaccination using purified porin protein also generated a protec-
tive immune response in Zfp36aa/aa mice. The behavior of
Zfp36aa/aa T cells has not yet been investigated in detail, but their
expression of IFN-g was shown to be unimpaired. Clearly, the
development of an acquired immune response depends on some
functions of innate immune cells, for example Ag presentation.
Until such functions have been analyzed in detail we can only
conclude that both innate and adaptive immune functions are
sufficient for clearance of a model pathogen in Zfp36aa/aa mice.
This suggests that targeting the TTP phosphorylation/dephos-
phorylation equilibrium may incur relatively low costs in terms
of response to infection. However, the subtle adaptive immune
phenotype described in the present study might confer a signifi-
cant decrease of fitness in the wild, for example in the face of
challenge with more virulent pathogens, or there may be some
other selective disadvantage that has not yet come to light.
In conclusion, the results described in the present study provide
strong evidence that the equilibrium between phosphorylated
and unphosphorylated TTP (with respect to Ser52 and Ser178) is
a critical determinant of the strength of inflammatory responses
in vitro and in vivo. They also provide proof of the concept that
this equilibrium might be targeted as a means of treatment of
inflammatory pathology, which may escape some of the problems
that have been associated with direct targeting of p38 MAPK
itself. Finally, they provide unambiguous corroboration of a working
model of TTP expression and function, which to this point was based
largely on in vitro assays and overexpression of TTP in transfected
cells.
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